bexarotene has been researched along with gw 3965 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrara, SJ; Scanlan, TS | 1 |
| Goduni, E; Jay, T; Lamb, BT; Landreth, GE; Malm, T; Mariani, MM; Quigley, C; Ransohoff, RM; Savage, JC | 1 |
2 other study(ies) available for bexarotene and gw 3965
| Article | Year |
|---|---|
A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators.
Topics: Amides; Amidohydrolases; Animals; Blood-Brain Barrier; Brain; Diffusion; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Prodrugs; Receptors, Cytoplasmic and Nuclear; Tissue Distribution | 2020 |
Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Axl Receptor Tyrosine Kinase; Benzoates; Benzylamines; Bexarotene; c-Mer Tyrosine Kinase; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation; Leukocyte Common Antigens; Macrophages; Male; Membrane Glycoproteins; Mice; Microglia; Myeloid Cells; Phagocytosis; Pioglitazone; Plaque, Amyloid; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Tetrahydronaphthalenes; Thiazoles; Thiazolidinediones | 2015 |